Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Belite Bio, Inc. Sponsored ADR (BLTE : NSDQ)

• Company Description    Belite Bio Inc. is a clinical stage biopharmaceutical drug development company focused on novel therapeutics targeting currently untreatable eye diseases involving retinal degeneration, such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease, and metabolic diseases. Belite Bio Inc. is based in SAN DIEGO. Number of Employees: 25

• Price / Volume Information    Yesterday's Closing Price: $62.03 Daily Weekly Monthly 20 Day Moving Average: 49,571 shares Shares Outstanding: 31.84 (millions) Market Capitalization: $1,974.89 (millions) Beta: -1.50 52 Week High: $86.53 52 Week Low: $43.70 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -0.18% -3.92% 12 Week 9.98% -7.49% Year To Date -1.70% -7.94%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 12750 HIGH BLUFF DRIVE SUITE 475 - SAN DIEGO,CA 92130 USA ph: 858-246-6240 fax: - ir@belitebio.com http://www.belitebio.com

• General Corporate Information    Officers Yu-Hsin Lin - Chief Executive Officer; Chairman of the Board Hao-Yuan Chuang - Chief Financial Officer Wan-Shan Chen - Director John M. Longo - Director Gary C. Biddle - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 07782B104 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/08/25 Share - Related Items Shares Outstanding: 31.84 Most Recent Split Date: (:1) Beta: -1.50 Market Capitalization: $1,974.89 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.47 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.75 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/08/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 12.49 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -66.67% vs. Previous Quarter: -40.62% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -32.07 12/31/24 - -30.82 ROA 06/30/25 - - 03/31/25 - -30.91 12/31/24 - -29.66 Current Ratio 06/30/25 - - 03/31/25 - - 12/31/24 - 24.31 Quick Ratio 06/30/25 - - 03/31/25 - - 12/31/24 - 24.31 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 4.96 12/31/24 - 4.72 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©